RxDoctor Payments Data

Sanjeev Saksena, MD

Clinical Cardiac Electrophysiology · Warren, NJNPI 1295836294

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $36,447 of the $57,267 with a category attached, or 63.6%. Sanofi-aventis U.S. LLC accounts for 97.9% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $22,503 and has fallen 99.2% since, to $190 in 2024.

$57,267in general payments, 2019–2025

Across 34 payments — averaging $1684.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$56K
  • Abbott$585
  • Biotronik Inc.$332
  • Medtronic$285
  • Irhythm Technologies, Inc.$24
$855,718in research payments, 2019–2025

Across 20 payments — averaging $42,786 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$853K
  • Sanofi-aventis U.S. LLC$2K

What the payments were for

  • Consulting fees$36,44764%
  • Speaking & faculty fees$19,48234%
  • Food & beverage$1,3382%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$57,267 in reported general payments places this provider in the 85th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.

See all clinical cardiac electrophysiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$40,512
Medicare patients
440
Services billed
890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MultaqDronedarone Hcl26$36,931
EntrestoSacubitril/Valsartan16$15,223
FarxigaDapagliflozin Propanediol12$14,128
EliquisApixaban12$12,910
Telmisartan13$1,062
Metoprolol Succinate51$1,041
Atorvastatin Calcium79$926
Potassium Chloride18$740
Amiodarone Hcl35$638
Ezetimibe24$569
Digoxin22$450
SotalolSotalol Hcl11$304
Losartan Potassium21$232
Furosemide52$220
ClopidogrelClopidogrel Bisulfate27$219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sanofi-aventis U.S. LLCMultaq$56,040$36,93126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.

Other clinical cardiac electrophysiology in Warren

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →